Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency TranscriptSeeking Alpha • 03/26/26
Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein LevelsBenzinga • 03/25/26
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal DevelopmentGlobeNewsWire • 03/25/26
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?Zacks Investment Research • 03/12/26
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue EstimatesZacks Investment Research • 02/24/26
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)GlobeNewsWire • 02/24/26
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth StreetGlobeNewsWire • 02/24/26
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease ProgramGlobeNewsWire • 02/23/26
Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock RisesZacks Investment Research • 01/13/26
Beam Soars Nearly 30% As FDA Signs Off On Its Ambitious Gene-Editing PlanInvestors Business Daily • 01/12/26
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial TransitionGlobeNewsWire • 01/11/26
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry?Zacks Investment Research • 12/31/25
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/18/25
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/06/25
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On GoalSeeking Alpha • 12/04/25
Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report?Zacks Investment Research • 12/04/25